Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices ... ...

Key Takeaways Amgen launched AmgenNow, offering direct discounts starting with its cholesterol drug Repatha.Repatha's new $239 monthly price marks a nearly 60% cut from its U.S. list price.Amgen partnered with GoodRx to make Repatha available at this price across 70,000 pharmacies.Amgen (AMGN) announced the launch of a new direct-to-consumer (DTC) program called AmgenNow, which will offer significant discounts on its marketed drugs. The company has initiated this DTC program with its blockbuster cholesterol ...

European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exchange for tariff relief. ...

Americans enrolled in Medicaid will get "most-favored-nations" pricing, the president said, meaning the U.S. drug prices would match the lower prices of other developed countries. Pfizer will also sell drugs at a direct-to- consumer website that has been dubbed TrumpRx. The government is setting up the website, which will allow Americans to buy medications at prices the government negotiates. Pfizer shares remain in the red for 2025 despite Tuesday's pop. Â ANGELA WEISS / AFP via Getty Images Close KEY TAKE ...

Today, Pfizer's committing to offer all of their prescription medications to Medicaid, and it will be at the most favored nations. Prices is going to have a huge impact on bringing Medicaid costs down like nothing else. I told you that in my first term, I was so proud of the fact that for the first time in 28 years, drug prices came down and I had a news conference that explained it was 1/10 of 1%, but it was down.And here we're talking about, in one case, over 1,000%. This is a critical step forward to wor ...

For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. They paid far more, 10 times, 13 times, 15 times more than other countries for the exact same product. A major reason is that the American consumers have been subsidizing research and development costs for the entire planet.They put all of that on us and yet they were the beneficiaries to. So, it's being changed as of today. The United States had just 4% of the world's population and consumers, only 13% of a ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America's role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President's July 31st letter, Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in o. ...

Core Insights - Novo Nordisk is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the U.S. This follows a similar price cut for its weight-loss drug Wegovy, which is also priced at $499 [1][4] - Eli Lilly has announced plans to expand the supply and reduce costs of its weight-loss drug Zepbound, enhancing access for uninsured patients through its self-pay pharmacy [2][4] - Novo Nordisk's Ozempic will be available through its NovoCare pharmacy program and in partnership with telehealth service GoodRx, also at the price of $499 per month [6] Company Performance - Novo Nordisk's stock price increased by 4.60%, closing at $54.39 following the announcement of the price cut for Wegovy [4] - Eli Lilly's stock price rose by 2.68%, reaching $701.23, as it benefits from the increased demand for its weight-loss drugs [6] - GoodRx's stock price surged nearly 30% to $5.06 after the announcement of the partnership with Novo Nordisk [7] Market Context - The U.S. administration, under President Trump, is focused on lowering drug prices, with an executive order aimed at aligning U.S. drug prices with those in other countries [7][10] - A notable example highlighted by Trump involved a significant price discrepancy for the same drug purchased in New York and London, emphasizing the ongoing issue of high drug costs in the U.S. [10]

Group 1 - Pfizer Inc's shares increased by 4.9% to $24.4 following better-than-expected second-quarter results and an improved profit outlook for 2025, driven by strong performance in Covid-19 drugs and Vyndaqel heart medication [1] - The company is facing pressure from President Donald Trump's demand for lower drug prices, but it claims its current guidance accounts for tariffs and cost-cutting measures [2] - Pfizer is discontinuing another GLP-1 drug from its weight-loss program, which has been struggling [2] Group 2 - There has been significant options activity for Pfizer, with 89,000 calls traded, which is double the average, compared to only 20,000 puts, indicating bullish sentiment [3] - The most active options are the August 25 call and the weekly 8/8 25-strike call [3]

Core Viewpoint - The weight-loss drug sector, currently a hot segment in the pharmaceutical market, experienced a decline in stock prices following President Trump's announcement regarding drug pricing reforms [1][2]. Group 1: Stock Market Reaction - Novo Nordisk, a leading company in obesity treatments, saw its share price drop nearly 4% [2] - Competitors Roche Holdings and Viking Therapeutics also experienced declines of approximately 3% and 2%, respectively [2]. Group 2: Government Initiatives - The White House is actively pursuing initiatives to lower drug prices, with President Trump signing an executive order aimed at this goal [3][4]. - A key requirement of the executive order is that U.S. drug prices must align with lower prices in foreign markets, with a compliance deadline of 30 days [4]. Group 3: Focus on Weight-Loss Drugs - Trump criticized the high prices of weight-loss drugs, citing a significant price difference between the U.S. and London for an unnamed medication [6]. - The two popular GLP-1 weight-loss treatments, Novo Nordisk's Wegovy and Eli Lilly's Zepbound, can exceed $1,000 for a month's supply [7]. Group 4: Future Implications - Although the executive order does not specifically mention weight-loss drugs, there is an expectation that GLP-1 treatments will be targeted for price reductions [8]. - The ambiguity of the executive order may have prevented a more severe stock market reaction from investors [9]. - Successful implementation of drug price reductions could disproportionately impact obesity drug developers compared to established pharmaceutical companies with diverse product lines [10].